Siemens Digitalization & Sustainable Solutions Ensure Labs are Safe, Secure and Compliant. Life Science Solutions from Siemens: Leading the Way in Science. Learn More Today!
- Contact us
Contact us for more information
about our products and services.
- Scale up production
Smart life science technologies
can optimize your project timelines
- Security for your lab
Free Whitepaper Download
Protect Critical Environments
- Journey along a smart lab
Linking operational efficiency &
worker safety to stay ahead.
- Contact us
Suchergebnisse
Suchergebnisse:
Juniper Biologics Pte Ltd, a top science-led pharmaceutical company focused on researching, developing and commercializing novel therapies.
- Pipeline
Pipeline - Juniper Biologics. Pipeline for continuous...
- ESG
Building action-oriented ESG efforts across our business....
- About Us
We are a science-led healthcare company focused on...
- Portfolio
We are proud to be making a profound difference in the lives...
- News
Juniper Biologics Named “Pharmaceutical Company of the Year”...
- Contact Us
JUNIPER BIOLOGICS FZ-LLC. VD-F13-135/136, 13th Floor,...
- Message From The CEO
We are focused on the transformation of Juniper’s business...
- Our Leadership Team
Benedict Ong is Chief Commercial Officer of Juniper...
- Pipeline
Juniper Biologics is a Singapore-based company that develops and commercialises novel therapies for oncology, rare/orphan diseases and gene therapy. It has operations in Asia, Australia, New Zealand, Middle East and Africa.
3. Juli 2018 · Juniper will now provide similar capabilities in the U.K. and will complement Catalent’s multi-site oral manufacturing network to provide pharmaceutical innovators with a comprehensive solution to accelerate their drug development processes.
Pipeline - Juniper Biologics. Pipeline for continuous benefit to patients. We’re working to identify more unmet medical needs and focus our research where it is needed most.
US-based drug delivery technology company Catalent has agreed to purchase all outstanding shares of specialty healthcare firm Juniper Pharmaceuticals for a total cash consideration of $139.6m, which represents $11.50 per share.
3. Juli 2018 · clinical manuacturing M&A Catalent Juniper Pharmaceuticals. Somerset, New Jersey-based CDMO Catalent is continuing its investment and expansion campaign, announcing Tuesday that it will buy...
15. Aug. 2018 · Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based Juniper Pharmaceuticals for $11.50 per share, or a total value of $130 million. The acquisition will strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.
